<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773656</url>
  </required_header>
  <id_info>
    <org_study_id>AOM 08234</org_study_id>
    <nct_id>NCT00773656</nct_id>
  </id_info>
  <brief_title>Patients Overexposed for a Prostate Adenocarcinoma</brief_title>
  <acronym>EPOPA</acronym>
  <official_title>Surveillance of the Cohort of Patients Overexposed in a Course of Conformational Radiotherapy for a Prostate Adenocarcinoma in Jean MONNET Hospital, Epinal, France. Epinal: Patients Overexposed for a Prostate Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Between 2000 and 2006, 433 patients were overexposed (8% to 10%) during a course of conformal&#xD;
      radiotherapy for a prostate adenocarcinoma in Jean MONNET hospital, Epinal, France. Among&#xD;
      them, twenty four patients received an additional mean dose about 20%, due to an&#xD;
      inappropriate use of the treatment planning system. Severe adverse events (proctitis,&#xD;
      cystitis, and tissue necrosis) have occurred among most of these overexposed patients. We&#xD;
      propose to develop several research programs in order to increase the scientific knowledge on&#xD;
      iatrogenic effects related to overexposure of ionizing radiation, by studying their&#xD;
      relationship with dosimetric, clinical, biologic and genetic characteristics.&#xD;
&#xD;
      Aim of the study:&#xD;
&#xD;
      To correlate the received doses, the volume of irradiated normal tissues, the events, with&#xD;
      biologic, phenotypic and genetic data.&#xD;
&#xD;
      Primary study endpoint:&#xD;
&#xD;
      Incidence and severity of adverse events related to radiotherapy (according to SOMA - LENT&#xD;
      and CTCAE scales).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary study endpoint:&#xD;
&#xD;
        -  Correlation between adverse events and radiation doses with biologic, phenotypic and&#xD;
           genetic data.&#xD;
&#xD;
        -  Evaluation of T-lymphocyte apoptosis to predict radiation-induced late toxicity&#xD;
&#xD;
        -  Gene associations with risks for adverse events related to radiotherapy&#xD;
&#xD;
        -  Levels of circulating microparticles and bystander effect after irradiation&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Consecutive patients treated for a prostate adenocarcinoma in the radiation department of the&#xD;
      Jean MONNET Hospital between 2000 and 2006.&#xD;
&#xD;
      Potential. Better identification of patients at high risk of adverse events related to&#xD;
      radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To correlate the received doses, the volume of irradiated normal tissues, the events, with biologic, phenotypic and genetic data.</measure>
    <time_frame>At the inclusion visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between adverse events and radiation doses with biologic, phenotypic and genetic data.</measure>
    <time_frame>At the inclusion visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of T-lymphocyte apoptosis to predict radiation-induced late toxicity</measure>
    <time_frame>At the inclusion visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene associations with risks for adverse events related to radiotherapy</measure>
    <time_frame>At the inclusion visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of circulating microparticles and bystander effect after irradiation</measure>
    <time_frame>At the inclusion visit</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">249</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients treated for a prostate adenocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole blood sample</intervention_name>
    <description>70 ml per patient for collection of biological sample</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      White cells, serum and DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients treated for a prostate adenocarcinoma in the radiation department of&#xD;
        the Jean MONNET Hospital between 2000 and 2006.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  provision of informed consent&#xD;
&#xD;
          -  patient treated for prostate adenocarcinoma and overexposed during radiotherapy in a&#xD;
             prostate adenocarcinoma in the radiation department of the a prostate adenocarcinoma&#xD;
             in the radiation department of the Jean MONNET hospital/ service de radiotherapies&#xD;
             between 2000 and 2006&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No provision of informed consent&#xD;
&#xD;
          -  Patient with disease worsening and in incapacity to move about to CHJM&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Marc SIMON, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Alsbeih G, El-Sebaie M, Al-Harbi N, Al-Buhairi M, Al-Hadyan K, Al-Rajhi N. Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):229-35. Epub 2007 Feb 27.</citation>
    <PMID>17331670</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Biologically effective dose</keyword>
  <keyword>Radiation injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

